Juan Carlos Gómez

Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients

Luis Prieto, José Antonio Sacristán, Juan A Hormaechea et al. · Current Medical Research and Opinion · 2004 · 85 citations

Medicine, Pharmacotherapy, Psychiatry +17

A Randomized, 1-Year Follow-up Study of Olanzapine and Risperidone in the Treatment of Negative Symptoms in Outpatients with Schizophrenia

Antonio Ciudad, José Manuel Olivares, Manuel Bousoño et al. · Journal of Clinical Psychopharmacology · 2006 · 63 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study

José Manuel García Montes, Antonio Ciudad, Josep Gascón et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2003 · 49 citations

Medicine, Pharmacotherapy, Psychiatry +14

Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial

Antonio Ciudad, J.M. Olivares, Manuel Bousoño et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2006 · 24 citations

Medicine, Psychiatry, Psychology +15

Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.

Gurutz Linazasoro, José Á. Obeso, Juan Carlos Gómez et al. · PubMed · 1999 · 19 citations

Life Sciences, Neuroscience, Pharmacology +16